bearish

Hang Seng Biotech Index Rebalance Preview: One Set of Changes in June

300 Views05 May 2026 07:14
InSilico Medicine Cayman could replace Everest Medicines in the index in June. Estimated one-way turnover at the rebalance is 2.2% resulting in a round-trip trade of HK$422m.
What is covered in the Full Insight:
  • Introduction
  • Review Process of Hang Seng Biotech Index
  • Expected Changes at the June Review
  • Estimated Passive Flow
  • Conclusions
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
x